Hostname: page-component-cd9895bd7-fscjk Total loading time: 0 Render date: 2024-12-18T16:42:10.542Z Has data issue: false hasContentIssue false
  • English
  • Français

Effect of three different doses of urapidil on blood glucose concentrations in the streptozotocin diabetic rat

Published online by Cambridge University Press:  16 August 2006

K. P. Ittner ,
M. Bucher ,
M. Zimmermann ,
H. F. Grobecker ,
B. K. Krämer  and
K. Taeger
K. P. Ittner
Affiliation:
University of Regensburg, Department of Anaesthesiology, Regensburg, Germany University of Regensburg, Department of Pharmacology, Regensburg, Germany
M. Bucher
Affiliation:
University of Regensburg, Department of Anaesthesiology, Regensburg, Germany
M. Zimmermann
Affiliation:
University of Regensburg, Department of Anaesthesiology, Regensburg, Germany
H. F. Grobecker
Affiliation:
University of Regensburg, Department of Pharmacology, Regensburg, Germany
B. K. Krämer
Affiliation:
University of Regensburg, Department of Internal Medicine II, Regensburg, Germany
K. Taeger
Affiliation:
University of Regensburg, Department of Anaesthesiology, Regensburg, Germany
Get access

Abstract

Background and objective: Diabetes mellitus associated with hypertension often causes perioperative complications. The α1-adrenoceptor antagonist/5-hydroxytryptamine-1A receptor agonist urapidil is an approved drug used in hypertension and hypertensive emergencies. 5-Hydroxytryptamine-1A (5-HT1A) receptor agonists impair glucose metabolism. To evaluate a possible dose-dependent hyperglycaemic effect of urapidil due to its 5-HT1A receptor agonistic properties, the effect of three doses of urapidil on hyperglycaemia in the streptozotocin diabetic rat was investigated.

Methods: Male Wistar-Kyoto rats were made diabetic by streptozotocin and randomly allocated to the following daily treatments for 7 days (n = 6 each): urapidil 6 mg kg−1, urapidil 20 mg kg−1, urapidil 60 mg kg−1, insulin 4 IU kg−1 subcutaneously. One diabetic group and one non-diabetic healthy group served as controls.

Results: Treatment for 7 days with urapidil 20 mg kg−1 and urapidil 60 mg kg−01 reduced mean glucose concentrations significantly (urapidil-20: 15.6 ± 1.1 mmol L−1P = 0.023; urapidil-60: 15.8 ± 0.8 mmol L−1, P = 0.04) compared with diabetic controls (20.9 ± 0.8 mmol L−1), whereas those after urapidil 6 mg kg−1 were similar to diabetic controls. Insulin treatment normalized blood glucose concentrations.

Conclusions: The α1-adrenoceptor antagonist/5-HT1A receptor agonist urapidil has no hyperglycaemic effect on experimental diabetes mellitus, even in high doses, despite its 5-HT1A receptor agonistic properties.

Keywords

adrenergic agentsadrenergic alpha antagonistsantihypertensive agentsdiabetes mellitusexperimentalnitrosourea compoundsstreptozocinserotonin agonistsurapidil
Type
Original Article
Information
European Journal of Anaesthesiology , Volume 19 , Issue 7 , July 2002 , pp. 504 - 509
Copyright
2002 European Society of Anaesthesiology

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)